Further research has implicated exposure to DEHP (from 0.05 to 500 mg/kg) with deregulation of insulin signaling in rats and humans via PPAR-γ activation, diminishing the liver’s capacity to maintain glucose homeostasis and contributing to insulin resistance [116], ultimately leading to adverse outcomes, such as chronic liver disease, type 2 diabetes, and cardiovascular disease [139,140,141]. The gene discussed is INS; the disease is cardiovascular disorder.